Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma
BackgroundThis study evaluated the cost-effectiveness of Atezolizumab plus Bevacizumab versus Rivoceranib plus Camrelizumab as first-line treatment of unresectable hepatocellular carcinoma (HCC) from the perspective of healthcare payers in China.MethodsAn economic evaluation using a 3-state partitio...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2026-06-01
|
| Ráidu: | Frontiers in Public Health |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/fpubh.2026.1749414/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|